CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-02 | WENTWORTH KORY JAMES Chief Financial Officer | Sale | −1,602 | $10.46 | $17K | 42,302 |
| 2023-03-02 | WENTWORTH KORY JAMES Chief Financial Officer | Sale | −145 | $11.23 | $2K | 42,157 |
| 2023-03-02 | Sethuraman Natarajan Chief Scientific Officer | Shares withheld for taxes | −1,058 | $11.60 | $12K | 189,486 |
| 2023-03-02 | Doshi Dipal President and CEO | Shares withheld for taxes | −3,324 | $11.60 | $39K | 257,811 |
| 2023-03-02 | Dowden Nathan J Chief Operating Officer | Shares withheld for taxes | −1,028 | $11.60 | $12K | 72,655 |
| 2023-03-02 | KREHER NERISSA Chief Medical Officer | Shares withheld for taxes | −945 | $11.60 | $11K | 42,971 |
| 2023-03-02 | KREHER NERISSA Chief Medical Officer | Sale | −1,477 | $10.49 | $15K | 41,494 |
| 2023-03-02 | KREHER NERISSA Chief Medical Officer | Sale | −164 | $11.22 | $2K | 41,330 |
| 2023-03-01 | Doshi Dipal President and CEO | Grant or award | +49,650 | 206,161 | ||
| 2023-03-01 | Doshi Dipal President and CEO | Grant or award · Stock Option (Right to Buy) | +75,250 | 75,250 | ||
| 2023-03-01 | Sethuraman Natarajan Chief Scientific Officer | Grant or award | +14,200 | 175,286 | ||
| 2023-03-01 | Sethuraman Natarajan Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +21,500 | 21,500 | ||
| 2023-03-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award | +14,200 | 27,957 | ||
| 2023-03-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +21,500 | 21,500 | ||
| 2023-03-01 | KREHER NERISSA Chief Medical Officer | Grant or award | +14,200 | 27,130 | ||
| 2023-03-01 | KREHER NERISSA Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +21,500 | 21,500 | ||
| 2023-03-01 | Dowden Nathan J Chief Operating Officer | Grant or award | +14,200 | 58,455 | ||
| 2023-03-01 | Dowden Nathan J Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +21,500 | 21,500 | ||
| 2023-03-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award | +28,400 | 44,909 | ||
| 2023-03-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +43,000 | 43,000 |
Page 17 of 26 · 517 trades